Vaccine could be sold without profits or licensing fees in Britain and low- and middle-income countries
MONDAY, June 8, 2020 (HealthDay News) — A partnership that would bypass the drug industry to sell a potential vaccine against the new coronavirus has been formed by a laboratory at Imperial College London.
The move would mean the vaccine could be sold without profits or licensing fees in Britain and in low- and middle-income countries, The New York Times reported. To be successful, a vaccine against the new coronavirus would have to be available at the lowest possible price and according to need rather than profit.
The Imperial College London lab has technology that may enable it to create a vaccine that is cheaper and easier to produce than others, said project lead scientist Robin Shattock, The Times reported.
Clinical trials of the vaccine are scheduled to start this month. If it proves safe and effective, the vaccine could become available early next year.
Nearly 3 in 4 Older Adults Express Interest in Vaccine to Prevent Dementia
Updated COVID-19 Shot Beneficial for Those With Autoimmune Rheumatic Disease
Trends Reported in Vaccination Coverage for Adolescents for 2025
AAP Issues Recommendations for Pediatric RSV Vaccination in 2026-2027 Season
4CMenB Vaccine Confers Modest Protection Against Gonorrhea in Teens
AAP Releases Influenza Vaccine Recommendations for All Children 6 Months and Older
Adverse Event Risk Not Up With Same Day COVID-19, Flu Vaccination